Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 4/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4207596 | 0.78 | PLG (0.45) | PLAUPLG | |
| SCHEMBL3377324 | 0.78 | ERBB2 (0.43) | TLR7CYP2C19EGFR | |
| SCHEMBL7086252 | 0.74 | HTR6 (0.54) | PRKCIHTR6PLAUEGFRPLG | |
| SCHEMBL31661563 | 0.74 | HTR6 (0.54) | PRKCIHTR6PLAUEGFRPLG | |
| SCHEMBL31661504 | 0.73 | SLC2A1 (0.54) | TLR7PRKCIHTR6PLAUCYP2C19 | |
| SCHEMBL3507524 | 0.73 | SLC2A1 (0.54) | TLR7PRKCIHTR6PLAUCYP2C19 | |
| SCHEMBL31036110 | 0.72 | MAOB (0.42) | PRKCIHTR6PLAUEGFRNTSR1 | |
| SCHEMBL29263685 | 0.72 | MAOB (0.42) | PRKCIHTR6PLAUEGFRNTSR1 | |
| SCHEMBL3509678 | 0.72 | PRKCI (0.41) | PRKCIHTR6PLAUEGFRNTSR1 | |
| SCHEMBL30365023 | 0.72 | PRKCI (0.41) | PRKCIHTR6PLAUEGFRNTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-09-24 | — | — | US | disclosed |
| CN-101365695-A | Quinazoline derivatives as anticancer agents | ASTRAZENECA AB (SE) | 2009-02-11 | — | — | CN | disclosed |
| EP-1940825-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007034143-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ABL1, ERBB2, CDK2 | TLR7 768/4885PRKCI 1133/4885HTR6 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.